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Key messages
What is already known about this subject? 
 ► Switching from originator to cheaper biosimilar bi-
ological agents has been suggested for economic 
reasons among patients with inflammatory arthritis. 
 ► existing literature provides no data about the cost 
consequences of such non-medical switching.
What does this study add? 
 ► We found no evidence of changes in use of outpa-
tient health resources following switch from origina-
tor to biosimilar infliximab. 
How might this impact on clinical practice? 
 ► this study demonstrated no immediate cost conse-
quences of non-medical switching in routine care. 
AbstrAct 
Objectives national Danish guidelines in May 2015 
dictated a mandatory switch from originator infliximab 
(inX) to biosimilar ct-P13 in patients with inflammatory 
rheumatic disease. We investigated if this non-medical 
switch changed use of outpatient hospital resources.
Methods Observational cohort study. Switchers were 
identified in DanBiO. rheumatic outpatient contacts, 
visits and services were identified in the national Patient 
registry. the 6-month rate for (1) number of visits (or 
services) and (2) days with ≥1 visit (or service) were 
compared before/after switching (paired t-tests). Visits 
per week per patient before/after the switch date were 
analysed with graphical interrupted time-series analysis.
Results in 769 switchers (372 males, median age 
54 years (iQr 44–66)), 1484 outpatient contacts, 6718 
visits and 9243 days with services (693 on switch date) 
were identified. Mean visit rate was 3.89 before and 3.95 
after switch (p=0.35). total number of services was 19 752 
(2019 on switch date). Mean rates before/after switch for 
16 service categories were small and differences close to 
zero. Visits per week per patient appeared similar before/
after switch with peaks every ≈8 weeks (standard inX 
infusion interval).
Conclusion changes were marginal with no clinically 
relevant increase in use of outpatient health care resources 
6 months after compared with 6 months before mandatory 
switch from originator to biosimilar infliximab.
Availability of the cheaper biosimilar 
disease-modifying antirheumatic drugs 
(bsDMARDs) has raised financial incen-
tives to change treatment practice.1 2 Recent 
European League Against Rheumatism 
guidelines state that biosimilars should be 
included in treatment algorithms on equal 
terms as the originator.3 However, recom-
mendations are debated regarding non-med-
ical switching (ie, switching for economic 
reasons in patients on stable treatment with 
the originator).4–6
In May 2015, Danish nationwide guidelines 
dictated a mandatory switch from originator 
(Remicade, INX) to biosimilar infliximab 
(Remsima, CT-P13) since the cost of CT-P13 
was 36% of INX.7 Non-medical switching 
might potentially induce uncertainty for 
patients and lead to an increased number 
of contacts to the healthcare provider for 
patient education or closer monitoring of the 
disease.8–10 This could impose additional costs 
on healthcare services potentially off-setting 
savings from the cheaper product. Existing 
evidence provides no meaningful data about 
the cost consequences of switching. Previous 
budget impact and pharmacoeconomic anal-
yses in autoimmune diseases have mainly 
included drug costs and prescription patterns 
and disregarded the impact on use of health-
care services.2 11–13
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Table 1  (A) Rate of services per patient 6 months before and after the switch, the difference and p values (paired t-test); (B) 
number of patients with no registered use of services; and (C) number of patients with changes in number of services  
Service 
A. Mean rate of services per patient B. Non-users 
(% of all)  
C. Patients with changes in number of 
services, n (% of patients who change) 
Before After Difference P level Less Unchanged More 
Outpatient visit 1.44 1.45 0.00 0.91 427 (56) 107 (31) 139 (41) 96 (28) 
Nurse activity 0.61 0.58 –0.03 0.22 601 (78) 53 (32) 69 (41) 46 (27) 
csDMARD 0.30 0.32 0.02 0.36 595 (77) 73 (42) 27 (16) 74 (43) 
Intravenous needle 0.36 0.37 0.01 0.61 666 (87) 28 (27) 38 (37) 37 (36) 
Infliximab treatment 3.10 2.96 –0.13 <0.01 11 (1) 229 (30) 330 (44) 199 (26) 
Consultation regarding 
treatment 0.09 0.07 –0.02 0.12 723 (94) 24 (52) 5 (11) 17 (37) 
Phone consultation 1.03 1.17 0.14 0.03 237 (31) 219 (41) 65 (12) 248 (47) 
Patient guidance 0.35 0.49 0.14 <0.01 584 (76) 47 (25) 48 (26) 90 (49) 
Intravenous medication 0.03 0.11 0.08 <0.01 697 (91) 16 (22) 2 (3) 54 (75) 
Methotrexate 0.60 0.61 0.01 0.73 557 (72) 84 (40) 48 (23) 80 (38) 
US shoulder, elbow, hand 0.09 0.07 –0.02 0.23 689 (90) 42 (53) 7 (9) 31 (39) 
US hip, knee, foot 0.08 0.10 0.01 0.30 681 (90) 35 (40)4 10 (11) 43 (49) 
Clinical investigation 0.31 0.47 0.16 <0.01 552 (72) 53 (24) 63 (29) 101 (47) 
Clinical control 2.08 2.26 0.19 <0.01 206 (27) 153 (27) 198 (35) 212 (38) 
Observation 0.17 0.22 0.05 <0.01 714 (93) 7 (13) 22 (40) 26 (47) 
BP measurement 0.61 0.60 –0.01 0.70 611 (79) 39 (25) 75 (47) 44 (28) 
BP, blood pressure; csDMARD, conventional synthetic disease-modifying antirheumatic drug; US, ultrasound.
The nationwide clinical DANBIO registry prospectively 
collates detailed clinical information among patients 
with inflammatory arthritis.14 These data, combined 
with administrative national health registries, offer a 
unique opportunity to assess use of healthcare resources 
in relation to switching. Thus, we aimed to investigate if 
switching from INX to CT-P13 in patients with inflamma-
tory arthritis affected outpatient consultation rates and 
services provided within departments of rheumatology 6 
months after compared with 6 months before the switch.
MaTeRials and MeTHOds
study population
The study population was identified in DANBIO and 
included INX-treated patients (rheumatoid arthritis, 
psoriatic arthritis or axial spondyloarthritis) who 
switched from INX to CT-P13 between 20 March and 
1 January 2016 (=switchers).7 Treatment regimen and 
switch date were obtained from DANBIO. Switch date was 
validated by the local departments of rheumatology.7 Vital 
status (=alive) by 1 August 2016 was confirmed through 
the central person register. Only patients alive during the 
full 6-month observation period were included.
The Danish National Patient Registry is virtually 
complete. It is organised with one record for each patient 
contact (which could be a series of visits for the same 
health problem).15 Information on all hospital outpa-
tient contacts (completed and ongoing) was obtained. 
Patients were included if they had ≥1 outpatient contact 
related to inflammatory joint disease at departments 
that registered patients in DANBIO. In Denmark, infu-
sions with biological DMARDs are administered at these 
departments.
Each outpatient contact consists of a number of outpa-
tient visits (ie, physical visits) with corresponding visit 
dates and records of services provided. Services are coded 
by date and type of service. Only records for visits and 
services dated 0–6 months before and after the switch 
date were included in this analysis. Services were cate-
gorised into 16 meaningful groups of relevance to INX 
treatment for inflammatory rheumatic diseases (shown 
in table 1). All visits and services provided by physicians 
and nurses (but not secretaries) related to outpatient 
contacts were included in the analysis.
Analyses were performed in Stata V.15.1 (StataCorp). 
For individual switch patients, the following rates were 
calculated for the 6-month period before and after 
switch: (1) days with ≥1 outpatient visit and (2) number 
of visits. Similar calculations were done for outpatient 
services. Visits and services performed on the switch date 
were analysed separately.
Differences in rates before versus after switch were 
compared by paired t-tests.
Switchers were also categorised according to change 
in number of services (fewer/the same/more) before 
versus after switch, and the service rates were compared 
for these categories.
The weekly rate of outpatient visits before and after 
the switch date was analysed with graphical interrupted 
time-series analysis.16
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Figure 1 Identification of switch patients and relevant hospital contacts. N, patient numbers.
ResulTs
Patient cohort and outpatient contacts
Among 802 switchers identified in DANBIO, 769 patients 
were included in the analysis (figure 1). In these patients, 
5091 outpatient hospital contacts (completed and 
ongoing) were identified, whereof 1484 contacts were 
related to INX treatment at departments using DANBIO 
(figure 1). The 769 included patients had a total of 6718 
visits that occurred within 6 months before (n=2995, 
45%), on (689, 10%), or 6 months after (n=3034, 45%) 
the switch date. Overall, 19 752 services were provided 
(2019 of these were on the switch date).
days with visits 6 months before and after switch
Mean visit rate was 3.89 before and 3.95 after switch 
(p=0.35). After the switch, 239 patients (31%) had fewer 
(mean −1.6, SD 1.0), 271 patients (35%) had the same 
and 259 patients (34%) had more visits (mean 1.6, SD 
1.0) than before switch.
The weekly rate of visits per patient appeared stable 
during the time period (figure 2). The peaks observed 
approximately every 8 weeks were consistent with clinical 
practice (standard INX infusion interval).
days with services
The total number of days with services were 4131 before 
(mean 5.4 days SD 2.8) and 4400 after switch (mean 5.8 
days SD 2.8) (p<0.01, paired t-test). After the switch, 
259 patients (34%) had fewer (mean −2.4, SD 1.7), 169 
patients (22%) had the same and 341 patients (45%) 
(mean 2.6, SD 2.0) had more days with services than 
before switch.
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Figure 2 Weekly rates of physical visits per patient 6 
months before and 6 months after switching.
analysis of services provided
The rates of provided services declined after switch for 
INX treatment and increased for telephone consulta-
tions, patient guidance, intravenous medication, clinical 
investigations and controls, and observations. Numer-
ical differences were, however, small and close to zero 
(table 1).
The number of patients with changes in provided 
services before versus after switch (less/more) appeared 
similar (table 1)
disCussiOn
In this study of 769 patients with inflammatory arthritis 
who switched from INX to CT-P13 in routine care, we 
found only minor, clinically insignificant changes in the 
use of outpatient health resources during a 6-month time 
period after the switch compared with before the switch.
The biosimilars are expected to provide similar stan-
dard care at lower costs, thus facilitating better access 
to treatment and perhaps earlier treatment during the 
disease course, which has major potential social perspec-
tives.4 8 The availability of bsDMARDs has been reported 
to cause changes in prescription practice, although the 
uptake of bsDMRARD varies markedly between coun-
tries.8 Previous pharmacoeconomic and budget impact 
analyses have mainly included direct costs of the medi-
cation.11 13 To our knowledge, no previous studies have 
investigated the use of healthcare resources accompa-
nying switching to bsDMARDs.
Discussions on how to use the cheaper biosimilar drugs 
in patients on stable treatment with the originator drug 
are ongoing.5 6 According to the Danish guidelines, 
switching was mandatory and INX was no longer routinely 
available.17 Within few months, CT-P13 acquired the 
majority of the INX market share across indications in 
Denmark.18 We have previously reported 1-year effective-
ness outcomes in the patient cohort.7
In the current study of the impact of non-medical 
switch on the use of healthcare resources, we used three 
different indicators: physical visits, days with services 
and number of services provided. Neither gave indica-
tions of substantial changes after switching. The visit rate 
was unchanged, while the number of services increased 
slightly after the switch with a minor increase in tele-
phone consultations and clinical investigations/controls. 
However, these services were only provided for a small 
proportion of the patients (7%–16%). Although the use 
of telephone consultations increased slightly, the associ-
ated activity-based fee (DRG-tariffs (18€))19 is modest.
Previous studies have reported that patients and 
healthcare professionals often are somewhat reluctant 
to implement the use of bsDMARDs.9 Negative expecta-
tions (=nocebo effects) are suspected to have an impact 
on treatment effects and costs.10 20 21 It is reassuring that 
we found only minor changes in the use of healthcare 
resources, despite the switch being mandatory and that 
no specific strategy for patient information was set up. 
The fact that patients were informed about the switch 
at an already scheduled appointment could potentially 
reduce the nocebo effect—treatment was handled ‘as 
usual’. Some patients may not have been aware of the 
switch, but this cannot be explored with the available 
data.
This study has strengths and limitations. The availability 
of valid and virtually complete data from routine clinical 
and administrative national registries was a strength. The 
validity of diagnoses and treatments in DANBIO is high.22 
The switch date in DANBIO coincided with a physical visit 
for the vast majority of patients, only ≈10% of patients had 
no physical visit (figure 2) or service provided on that date. 
This might be due to imprecise registration in DANBIO 
or errors in data coding. The registration of physical visits 
and days with services in the national patient registry has 
high validity.15 Although there seemed to be some vari-
ation in the routines regarding registration of services 
between departments, the paired analyses were robust 
to such variation. The service rate during the 6-month 
period following switch seemed stable, which indicates 
that the time period that was chosen for the investigation 
of a potential impact of the switch was relevant. However, 
we have no information regarding the duration of the 
individual services provided; thus, if the switch induced 
longer and more elaborate consultations/phone calls, 
this has not been captured.
In conclusion, this study does not provide evidence of 
an increased use of outpatient healthcare resources in 
departments of rheumatology following the nationwide 
mandatory switch from originator to biosimilar INX.
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